The clinical impact of FAP-α was also tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP-α enzymatic activity, in a phase II study of patients with metastatic colorectal cancer. The gene discussed is FAP; the disease is metastatic colorectal cancer.